Aquestive Therapeutics (AQST) Other Non-Current Assets (2017 - 2026)

Aquestive Therapeutics' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 37.49% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 37.49% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, down 37.44% from the prior year.
• Other Non-Current Assets steadied at $2.6 million in Q1 2026 per AQST's latest filing, from $2.6 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $6.9 million in Q1 2022 and bottomed at $2.6 million in Q1 2026.
• The 5-year median for Other Non-Current Assets is $5.4 million (2024), against an average of $4.8 million.
• Across the five-year window, Other Non-Current Assets declined 5.82% in 2023 and tumbled 37.49% in 2026, its largest moves.
• Year by year, Other Non-Current Assets stood at $6.5 million in 2022, then fell by 15.7% to $5.4 million in 2023, then dropped by 22.34% to $4.2 million in 2024, then sank by 37.44% to $2.6 million in 2025, then fell by 0.26% to $2.6 million in 2026.
• Per Business Quant, the three latest AQST Other Non-Current Assets figures stand at $2.6 million (Q1 2026), $2.6 million (Q4 2025), and $3.2 million (Q3 2025).